Literature DB >> 21733936

The role of Factor V Leiden in adult patients with venous thromboembolism: a meta-analysis of published studies from Turkey.

Aydan Eroglu1, Durdu Sertkaya, Nejat Akar.   

Abstract

Factor V Leiden (FVL) is the most common inherited risk factor for venous thromboembolism (VTE). The frequency of FVL in patients with VTE has been reported from different parts of Turkey. A meta-analysis was performed to estimate the risk of VTE associated with FVL in Turkish population. Published studies were retrieved from Pubmed and Science Citation Index/Expanded. We selected studies comparing the prevalence of FVL in patients with VTE with controls. The analysis was performed by the software comprehensive meta-analysis. The analysis consisted of 10 studies including 1202 patients with VTE and 1283 controls. The pooled frequency of FVL was significantly higher in patients with VTE (22.8%) than controls (7.6%). The pooled odds ratio (OR) was 3.4 (95% confidence interval [CI], 2.6-4.5). The study showed homogeneity (Q value, 9.955). No publication bias was observed in any comparison model. Our meta-analysis showed an association of FVL with VTE in Turkey.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21733936     DOI: 10.1177/1076029611412369

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  3 in total

1.  The distribution of Factor V Leiden mutation.

Authors:  Aydan Eroğlu
Journal:  J Thromb Thrombolysis       Date:  2013-10       Impact factor: 2.300

2.  The prevalence of Factor V Leiden, prothrombin G20210A, MTHFR C677T and MTHFR A1298C mutations in healthy Turkish population.

Authors:  M Ekim; H Ekim; Y K Yılmaz
Journal:  Hippokratia       Date:  2015 Oct-Dec       Impact factor: 0.471

3.  Factor V Leiden and Prothrombin 20210A Mutations among Turkish Pediatric Leukemia Patients.

Authors:  Dilara Fatma Akın; Kadir Sipahi; Tuğba Kayaalp; Yonca Eğin; Serpil Taşdelen; Emin Kürekçi; Ustün Ezer; Nejat Akar
Journal:  Leuk Res Treatment       Date:  2012-02-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.